Strategic investments Olive Tree Capital actively deploys across multiple asset classes from an evergreen pool, indicating a willingness to participate in early-stage rounds and diverse opportunities. Targeting early seed to Series rounds across tech and biotech suggests potential to co-lead or participate in upcoming rounds you may be sourcing.

Diverse portfolio Recent and ongoing investments span biotech, healthcare technology, and blockchain interoperability, signaling openness to cross sector synergies. This breadth creates opportunities for partnerships or co-investments with portfolio companies in related verticals your network can access.

Active fundraising cadence Multiple seed to Series investments across 2022–2026 show a consistent capital deployment pattern. Engage Olive Tree Capital on new rounds by presenting compelling value propositions, traction, and clear use-of-funds aligned with their evergreen mandate.

Notable exit potential Investments in innovative platforms such as Axelar and Curacel indicate preference for scalable, defensible technology with broad market reach. Position opportunities that emphasize strong moat, regulatory navigation, and meaningful addressable markets to align with their growth thesis.

Strategic collaboration Participation from Olive Tree Capital in syndicated rounds alongside prominent investors suggests a preference for selective co-investment and strategic synergies. Propose co-investment milestones, expert networks, and potential strategic partnerships to attract their collaborative approach.